Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Opioid management strategy decreases admissions in high-utilizing adults with sickle cell disease
source: Journal of Opioid Management
year: 2017
authors: Mager A, Pelot K, Koch K, Miller L, Hubler C, Ndifor A, Coan C, Leonard C, Field JJ
summary/abstract:Background:
A subset of adults with sickle cell disease (scd) heavily utilizes the emergency department (ed) and hospital. The objective of our study was to determine the efficacy of a multidisciplinary strategy to address unmet needs in highly utilizing adults with scd.
Methods:
In a prospective study, adults with scd with ≥10 admissions per year were assessed by a multidisciplinary team for gaps in medical, social, and psychological care. Thereafter, the team decided upon the subject’s predominant domain that drove admissions and instituted an interventional plan. All plans included an opioid management strategy. Preintervention and postintervention admission rate, as well as opioid use, was compared.
Results:
Twelve subjects were enrolled. Median rate of ed and hospital admissions preintervention was 25 per year. The predominant domains identified were social needs (n = 6), psychological disorder (n = 1), and substance use disorder (n = 5). Multifaceted interventional plans were developed to address a wide range of gaps in care, but an opioid management strategy was the only intervention successfully completed. Even so, when the preintervention versus postintervention admission rate was compared, regardless of the domain, there was a 40 percent decline in hospital admissions (p = 0.03). Consistent with the successful implementation of an opioid management plan, the decrease in admissions was accompanied by a 37 percent decrease in intravenous opioid use (p = 0.02) and 10 percent decrease in oral opioid use (p = 0.04).
Conclusion:
An opioid management strategy, as part of a larger effort to improve care for high-utilizing adults with scd, decreased rate of admissions and opioid use.
DOI: 10.5055/jom.2017.0382
read more
+myBinderRelated Content
-
Spearheading change on World Sickle Cell DayThis year on World Sickle Cell Day, a ne...
-
Minority Health Counts: Building a More Equitable Community SummitBy Supporters of Families with Sickle Ce...
-
Potential treatment targeting nitric oxide levels, olinciguat, named orphan drug by FDAThe U.S. Food and Drug Administration ...
-
William Owen, MDDr. William Owen is a pediatric hematolo...
-
Early clinical trial data show gene therapy reversing sickle cell anemiaAfter over a decade of preclin...
-
A Developmental Examination of Pain Among Youth with Sickle Cell DiseaseIntroduction: Sickle cell disease (SCD)...
-
A randomized controlled trial of home-based computerized working memory training for children with sickle cell disea...Objectives: To determine the effects of...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.